Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.
From this RSS feed
You must log in or # to comment.
Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.
From this RSS feed